ADVERTISEMENT
A syringe delivering a fleet of DNA nanorobots to a cancer cell.
Building Biomolecular Machines
William Shih draws inspiration from origami and jigsaw puzzles in his quest to build bigger DNA nanorobots.
Building Biomolecular Machines
Building Biomolecular Machines

William Shih draws inspiration from origami and jigsaw puzzles in his quest to build bigger DNA nanorobots.

William Shih draws inspiration from origami and jigsaw puzzles in his quest to build bigger DNA nanorobots.

biochemistry, cancer

Abstract waves in red, orange, blue, and purple on a black background.
A Quick and Efficient Strategy for Affinity Screening
NanoTemper Technologies | Dec 7, 2023 | 1 min read
Researchers assessed the binding affinities of PROTAC binary and ternary complexes with Spectral Shift technology.
Conceptual illustration of molecular interactions.
A Solution for Measuring In-Solution Interactions 
NanoTemper Technologies | Dec 5, 2023 | 1 min read
Scientists used Spectral Shift assays to assess binding affinity and degradation of the oncogene regulator WDR5.
Black and gold sketch of the three prize winners.
Nobel Prize for Experiments With Light
Danielle Gerhard, PhD | Oct 3, 2023 | 4 min read
Anne L’Huillier, Pierre Agostini, and Ferenc Krausz received this year’s Physics award for creating tools for studying the world of electrons, with future applications in medical diagnostics.
Dogs under blanket together stock photo
A Nose by Any Other Name: Tracking the Scent of Tumor Metabolic Waste
Iris Kulbatski, PhD | Apr 11, 2022 | 3 min read
The unique odor profiles of tumors can be used to develop diagnostic sensing tools.
It’s Bittersweet: The Tumorigenic Potential of Glycosylation
It’s Bittersweet: The Tumorigenic Potential of Glycosylation
The Scientist Creative Services Team in collaboration with Vector Laboratories | Nov 9, 2021 | 1 min read
Karen Abbott and Susan Bellis discuss how to detect and block tumorigenic glycosylation signatures to diagnose and treat cancer.
Measuring Metabolites to Prevent, Diagnose, and Treat Cancer
Niki Spahich, PhD | Jun 11, 2021 | 1 min read
Metabolomics research highlights molecules important for cancer prevention, diagnosis, and treatment.
clpp onc201 cancer mechanism of action clinical trial
Found: A Cancer Drug’s Mechanism of Action
Ashley P. Taylor | May 21, 2019 | 4 min read
As ONC201 moves through human clinical trials, scientists finally figure out that the compound and its analogs target a mitochondrial protease.
Contributors
Catherine Offord | Apr 1, 2016 | 3 min read
Meet some of the people featured in the April 2016 issue of The Scientist.
Designing Transition-State Inhibitors
Vern L. Schramm | May 1, 2012 | 1 min read
A transition-state mimic has the power to bind an enzyme at its tipping point as strongly as any available inhibitor and more strongly than most, preventing enzymatic activity. 
Freezing Time
Vern L. Schramm | May 1, 2012 | 10+ min read
Targeting the briefest moment in chemistry may lead to an exceptionally strong new class of drugs.
David Sabatini: Demystifying mTOR
Cristina Luiggi | Mar 1, 2012 | 2 min read
Principal Investigator, Whitehead Institute for Biomedical Research. Associate Professor, Department of Biology, Massachusetts Institute of Technology. Age: 44
Shielding Cancer Cells from Damage
Tia Ghose | Nov 3, 2011 | 2 min read
An alternative form of an enzyme involved in the glucose metabolism pathway protects cancer cells from oxidative stress.
BRCA1 Further Elucidated
Cristina Luiggi | Oct 27, 2011 | 4 min read
Researchers have pinpointed the region of a key cancer gene that’s involved in tumor suppression.
ADVERTISEMENT